JP2006502086A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502086A5
JP2006502086A5 JP2003559480A JP2003559480A JP2006502086A5 JP 2006502086 A5 JP2006502086 A5 JP 2006502086A5 JP 2003559480 A JP2003559480 A JP 2003559480A JP 2003559480 A JP2003559480 A JP 2003559480A JP 2006502086 A5 JP2006502086 A5 JP 2006502086A5
Authority
JP
Japan
Prior art keywords
carbons
amino acid
branched
hydrogen
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003559480A
Other languages
English (en)
Japanese (ja)
Other versions
JP4959919B2 (ja
JP2006502086A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/041299 external-priority patent/WO2003059317A2/en
Publication of JP2006502086A publication Critical patent/JP2006502086A/ja
Publication of JP2006502086A5 publication Critical patent/JP2006502086A5/ja
Application granted granted Critical
Publication of JP4959919B2 publication Critical patent/JP4959919B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003559480A 2001-12-21 2002-12-20 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物 Expired - Fee Related JP4959919B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34278701P 2001-12-21 2001-12-21
US60/342,787 2001-12-21
PCT/US2002/041299 WO2003059317A2 (en) 2001-12-21 2002-12-20 Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Publications (3)

Publication Number Publication Date
JP2006502086A JP2006502086A (ja) 2006-01-19
JP2006502086A5 true JP2006502086A5 (https=) 2006-03-02
JP4959919B2 JP4959919B2 (ja) 2012-06-27

Family

ID=23343270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559480A Expired - Fee Related JP4959919B2 (ja) 2001-12-21 2002-12-20 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物

Country Status (8)

Country Link
US (1) US7718162B2 (https=)
EP (1) EP1458357B1 (https=)
JP (1) JP4959919B2 (https=)
AT (1) ATE424186T1 (https=)
AU (1) AU2002367032B8 (https=)
CA (1) CA2470520A1 (https=)
DE (1) DE60231428D1 (https=)
WO (1) WO2003059317A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231428D1 (de) 2001-12-21 2009-04-16 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
DE60228615D1 (de) * 2001-12-21 2008-10-09 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einer eine amid- und/oder estergruppe enthaltenden exzipientenverbindung
AU2002361850A1 (en) * 2001-12-21 2003-07-30 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0620700D0 (en) 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
CA2775404C (en) 2009-09-25 2017-01-03 Dr. Reddy's Laboratories Limited Formulations comprising triptan compounds
EP2512438B1 (en) 2009-12-16 2017-01-25 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve
BR112019027457A2 (pt) 2017-07-07 2020-07-07 Basf Se esteramina e sal da mesma, processo para preparação de esteramina ou sal da mesma, uso de esteramina e sal da mesma, e, composição de cuidados pessoais.
CN117042803A (zh) * 2021-12-02 2023-11-10 丽泽润有限公司 具有多功能应用的天然赋形剂及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1163028B (de) * 1960-03-09 1964-02-13 Hoechst Ag Verfahren zur Polymerisation von Vinylchlorid
US4863720A (en) 1986-03-10 1989-09-05 Walter Burghart Pharmaceutical preparation and methods for its production
US4869899A (en) * 1986-03-10 1989-09-26 Walter Burghart Pharmaceutical preparation and process for producing the same
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
CA2085884C (en) 1990-06-29 2001-12-04 Asit Somani Pressurized hydrofluorocarbon aerosol compositions
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
SK280911B6 (sk) 1992-12-09 2000-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Farmaceutický prostriedok
NZ263410A (en) 1993-03-17 1997-05-26 Minnesota Mining & Mfg Pharmaceutical aerosol containing diol-diacid derived dispersing aid
DE69413955T2 (de) * 1993-03-17 1999-04-01 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
DK0731688T3 (da) 1993-12-02 2003-06-23 Abbott Lab Aerosol-lægemiddelformuleringer til anvendelse med CFC-frie drivmidler
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6218353B1 (en) 1997-08-27 2001-04-17 Micell Technologies, Inc. Solid particulate propellant systems and aerosol containers employing the same
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DK1124535T3 (da) 1998-10-27 2003-01-06 Alcon Lab Inc Konserverende system til topisk indgivelige farmaceutiske præparater indeholdende en fedtsyre/aminosyresæbe
US6258857B1 (en) 1999-02-04 2001-07-10 Kyowa Industrial Co., Ltd. Internal liquid composition contained as internal liquid in a releasing container and releasing container product
GB0016876D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US7217409B2 (en) 2000-09-22 2007-05-15 Smithkline Beecham Corporation Alkanoic acid derivatives
JP2004535401A (ja) 2001-05-21 2004-11-25 ネクター セラピューティックス 化学的に改変されたインスリンの肺投与
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
DE60228615D1 (de) 2001-12-21 2008-10-09 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einer eine amid- und/oder estergruppe enthaltenden exzipientenverbindung
DE60231428D1 (de) 2001-12-21 2009-04-16 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff

Similar Documents

Publication Publication Date Title
JP2006502086A5 (https=)
Mimoto et al. Kynostatin (KNI)-227 and-272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine
JP4990155B2 (ja) プロテアソームを阻害するための組成物
JP3731899B2 (ja) 酸化窒素放出生体高分子含有医薬組成物
RU2191189C2 (ru) Производные замещенного пуринила, обладающие иммуномодуляторной активностью, фармацевтическая композиция и способ замедления роста опухоли
JP5537431B2 (ja) ウイルス融合のインヒビターのコレステロール誘導体
JPH05505824A (ja) 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用
WO2017211917A1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
ES2373561T3 (es) Uso de derivados de 1,4-bis(3-aminoalquil)piperazina en el tratamiento de enfermedades neurodegenerativas.
WO2019110838A1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
KR20120125610A (ko) 시클로스포린 유사체
Sohma et al. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage
JP2005514440A5 (https=)
CA3123368A1 (en) Mitochondria-targeting peptides
Robles et al. Solid-phase synthesis of a nucleopeptide from the linking site of adenovirus-2 nucleoprotein,-Ser (p 5′ CATCAT)-Gly-Asp-. Convergent versus stepwise strategy
EP2776471A1 (en) Stable peptide-based furin inhibitors
EP4166133A1 (en) Composition containing peptide compound and surfactant
DK149091C (da) Analogifremgangsmaade til fremstilling af peptider indeholdende 2-7 aminosyrerester, desaminodipeptider eller amider deraf med ubiquitin-lignende aktivitet eller farmaceutisk acceptable syreadditionssalte deraf
AU2008339610B2 (en) Methods of peptide modification
ES2361921T3 (es) Inhibidores duales antitrombóticos que comprenden un residuo de biotina.
ATE402949T1 (de) Dipeptidtransglutaminaseinhibitoren und verfahren zu deren anwendung
RU2003121303A (ru) Композиции, содержащие аддукты
KR870000360A (ko) 바조프레신 길항근
CN102731626B (zh) 环肽及其医药用途
Das et al. Molecular design and structure–activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664